MLICM
DYN icon

Metropolitan Life Insurance Company (MetLife)’s Dyne Therapeutics DYN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,137
Closed -$89.1K – 633
2024
Q1 		$89.1K Buy
3,137
+761
+32% +$17.2K ﹤0.01% 1109
2023
Q4 		$31.6K Hold
2,376
– – ﹤0.01% 1687
2023
Q3 		$21.3K Hold
2,376
– – ﹤0.01% 1862
2023
Q2 		$26.7K Buy
2,376
+326
+16% +$3.85K ﹤0.01% 1776
2023
Q1 		$23.6K Hold
2,050
– – ﹤0.01% 1793
2022
Q4 		$23.8K Sell
2,050
-532
-21% -$6.16K ﹤0.01% 1916
2022
Q3 		$32.8K Hold
2,582
– – ﹤0.01% 1741
2022
Q2 		$17.7K Hold
2,582
– – ﹤0.01% 2098
2022
Q1 		$24.9K Sell
2,582
-7,180
-74% -$61.1K ﹤0.01% 1991
2021
Q4 		$116K Buy
9,762
+2,725
+39% +$38.3K ﹤0.01% 2384
2021
Q3 		$114K Sell
7,037
-2,180
-24% -$38.6K ﹤0.01% 2452
2021
Q2 		$194K Buy
+9,217
New +$173K ﹤0.01% 2162
2021
Q1 		– Sell
-5,226
Closed -$110K – 2591
2020
Q4 		$110K Buy
+5,226
New +$103K ﹤0.01% 2312

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s DYN Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Dyne Therapeutics (DYN) in Q2 2024, closing a stake of 3,137 shares — an estimated $89.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in DYN in Q4 2020 and held it in 13 quarters. The position peaked at $194K in Q2 2021. 193 funds tracked by Wall St. Rank hold DYN as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Dyne Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,137 Dyne Therapeutics shares in Q2 2024, an estimated $89.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Dyne Therapeutics in Q4 2020 and held it in 13 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Dyne Therapeutics position peaked at $194K in Q2 2021.
  • 193 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.